ID: ALA24043

Max Phase: Preclinical

Molecular Formula: C29H22N4O2

Molecular Weight: 458.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1cccc(-c2cc(C#N)ccc2C#CC(O)(c2ccc(C#N)cc2)c2cncn2C)c1

Standard InChI:  InChI=1S/C29H22N4O2/c1-3-35-26-6-4-5-24(16-26)27-15-22(18-31)7-10-23(27)13-14-29(34,28-19-32-20-33(28)2)25-11-8-21(17-30)9-12-25/h4-12,15-16,19-20,34H,3H2,1-2H3

Standard InChI Key:  QYLBZDCYGRTUQE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.52

Molecular Weight (Monoisotopic): 458.1743

AlogP: 4.52

#Rotatable Bonds: 5

Polar Surface Area: 94.86

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.19

CX Basic pKa: 5.87

CX LogP: 4.56

CX LogD: 4.55

Aromatic Rings: 4

Heavy Atoms: 35

QED Weighted: 0.44

Np Likeness Score: -0.95

References

1. Lin NH, Wang L, Cohen J, Gu WZ, Frost D, Zhang H, Rosenberg S, Sham H..  (2003)  Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.,  13  (7): [PMID:12657267] [10.1016/s0960-894x(03)00122-7]

2. Lin NH, Wang L, Wang X, Wang GT, Cohen J, Gu WZ, Zhang H, Rosenberg SH, Sham HL..  (2004)  Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.,  14  (20): [PMID:15380198] [10.1016/j.bmcl.2004.07.083]

3. Equbal T, Silakari O, Rambabu G, Ravikumar M..  (2007)  Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.,  17  (6): [PMID:17236767] [10.1016/j.bmcl.2006.12.087]

Source

Source(1):

• Scientific Literature